Polymorphisms in NQO1 and the clinical course of urinary bladder neoplasms

References

• Ji J, Granstrom C, Hemminki K. Occupation and bladder cancer: a cohort study in Sweden. Br J Cancer 2005; 92: 1276–8
   PubMed Web of Science ®Google Scholar
• Steineck G, Plato N, Norell SE, Hogstedt C. Urothelial cancer and some industry-related chemicals: an evaluation of the epidemiologic literature. Am J Ind Med 1990; 17: 371–91
   PubMed Web of Science ®Google Scholar
• Steineck G, Norell SE, Feychting M. Diet, tobacco and urothelial cancer. A 14-year follow-up of 16,477 subjects. Acta Oncol 1988; 27: 323–7
   PubMed Web of Science ®Google Scholar
• Wijkstrom H, Cohen SM, Gardiner RA, Kakizoe T, Schoenberg M, Steineck G, et al. Prevention and treatment of urothelial premalignant and malignant lesions. Scand J Urol Nephrol Suppl 2000; 205: 116–35
   Google Scholar
• Raunio H, Husgafvel-Pursiainen K, Anttila S, Hietanen E, Hirvonen A, Pelkonen O. Diagnosis of polymorphisms in carcinogen-activating and inactivating enzymes and cancer susceptibility—a review. Gene 1995; 159: 113–21
   PubMed Web of Science ®Google Scholar
• Brockmoller J, Cascorbi I, Henning S, Meisel C, Roots I. Molecular genetics of cancer susceptibility. Pharmacology 2000; 61: 212–27
   PubMed Web of Science ®Google Scholar
• Loktionov A. Common gene polymorphisms, cancer progression and prognosis. Cancer Lett 2004; 208: 1–33
   PubMed Web of Science ®Google Scholar
• Johns LE, Houlston RS. Glutathione S-transferase mu1 (GSTM1) status and bladder cancer risk: a meta-analysis. Mutagenesis 2000; 15: 399–404
   PubMed Web of Science ®Google Scholar
• Johns LE, Houlston RS. N-acetyl transferase-2 and bladder cancer risk: a meta-analysis. Environ Mol Mutagen 2000; 36: 221–7
   PubMed Web of Science ®Google Scholar
• Engel LS, Taioli E, Pfeiffer R, Garcia-Closas M, Marcus PM, Lan Q, et al. Pooled analysis and meta-analysis of glutathione S-transferase M1 and bladder cancer: a HuGE review. Am J Epidemiol 2002; 156: 95–109
   PubMed Web of Science ®Google Scholar
• Saldivar SJ, Wang Y, Zhao H, Shao L, Lin J, Spitz MR, et al. An association between a NQO1 genetic polymorphism and risk of lung cancer. Mutat Res 2005; 582: 71–8
   PubMed Web of Science ®Google Scholar
• Choi JY, Lee KM, Cho SH, Kim SW, Choi HY, Lee SY, et al. CYP2E1 and NQO1 genotypes, smoking and bladder cancer. Pharmacogenetics 2003; 13: 349–55
   PubMedGoogle Scholar
• Karagas MR, Park S, Warren A, Hamilton J, Nelson HH, Mott LA, et al. Gender, smoking, glutathione-S-transferase variants and bladder cancer incidence: a population-based study. Cancer Lett 2005; 219: 63–9
   PubMed Web of Science ®Google Scholar
• Kim EJ, Jeong P, Quan C, Kim J, Bae SC, Yoon SJ, et al. Genotypes of TNF-alpha, VEGF, hOGG1, GSTM1, and GSTT1: useful determinants for clinical outcome of bladder cancer. Urology 2005; 65: 70–5
   PubMed Web of Science ®Google Scholar
• Srivastava DS, Kumar A, Mittal B, Mittal RD. Polymorphism of GSTM1 and GSTT1 genes in bladder cancer: a study from North India. Arch Toxicol 2004; 78: 430–4
   PubMed Web of Science ®Google Scholar
• Ma QW, Lin GF, Chen JG, Shen JH. Polymorphism of glutathione S-transferase T1, M1 and P1 genes in a Shanghai population: patients with occupational or non-occupational bladder cancer. Biomed Environ Sci 2002; 15: 253–60
   PubMed Web of Science ®Google Scholar
• Saad AA, O'Connor PJ, Mostafa MH, Metwalli NE, Cooper DP, Povey AC, et al. Glutathione S-transferase M1, T1 and P1 polymorphisms and bladder cancer risk in Egyptians. Int J Biol Markers 2005; 20: 69–72
   PubMed Web of Science ®Google Scholar
• Harris MJ, Coggan M, Langton L, Wilson SR, Board PG. Polymorphism of the Pi class glutathione S-transferase in normal populations and cancer patients. Pharmacogenetics 1998; 8: 27–31
   PubMedGoogle Scholar
• Sanyal S, Festa F, Sakano S, Zhang Z, Steineck G, Norming U, et al. Polymorphisms in DNA repair and metabolic genes in bladder cancer. Carcinogenesis 2004; 25: 729–34
   PubMed Web of Science ®Google Scholar
• Kimura F, Franke KH, Steinhoff C, Golka K, Roemer HC, Anastasiadis AG, et al. Methyl group metabolism gene polymorphisms and susceptibility to prostatic carcinoma. Prostate 2000; 45: 225–31
   PubMed Web of Science ®Google Scholar
• Moore LE, Wiencke JK, Bates MN, Zheng S, Rey OA, Smith AH. Investigation of genetic polymorphisms and smoking in a bladder cancer case-control study in Argentina. Cancer Lett 2004; 211: 199–207
   PubMed Web of Science ®Google Scholar
• Ryk C, Berggren P, Kumar R, Hemminki K, Larsson P, Steineck G, et al. Influence of GSTM1, GSTT1, GSTP1 and NAT2 genotypes on the p53 mutational spectrum in bladder tumours. Int J Cancer 2005; 113: 761–8
   PubMed Web of Science ®Google Scholar
• Sobin LH, Fleming ID. TNM Classification of Malignant Tumors, fifth edition . Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer ;80 1997; 1997: 1803–4
   Google Scholar
• Mostofi FK, Davis CJ, Sesterhenn IA. Histological typing of urinary bladder tumors. WHO, GenevaSwitzerland 1999
   Google Scholar
• Hall RR, Prout GR. Staging of bladder cancer: is the tumor, node, metastasis system adequate?. Semin Oncol 1990; 17: 517–23
   PubMed Web of Science ®Google Scholar
• Bergkvist A, Ljungqvist A, Moberger G. Classification of bladder tumours based on the cellular pattern. Preliminary report of a clinical-pathological study of 300 cases with a minimum follow-up of eight years. Acta Chir Scand 1965; 130: 371–8
   PubMedGoogle Scholar
• Malmstrom PU, Busch C, Norlen BJ. Recurrence, progression and survival in bladder cancer. A retrospective analysis of 232 patients with greater than or equal to 5-year follow-up. Scand J Urol Nephrol 1987; 21: 185–95
   PubMed Web of Science ®Google Scholar
• Larsson P, Wijkstrom H, Thorstenson A, Adolfsson J, Norming U, Wiklund P, et al. A population-based study of 538 patients with newly detected urinary bladder neoplasms followed during 5 years. Scand J Urol Nephrol 2003; 37: 195–201
   PubMed Web of Science ®Google Scholar
• Kumar R, Hoglund L, Zhao C, Forsti A, Snellman E, Hemminki K. Single nucleotide polymorphisms in the XPG gene: determination of role in DNA repair and breast cancer risk. Int J Cancer 2003; 103: 671–5
   PubMed Web of Science ®Google Scholar
• Asher G, Lotem J, Cohen B, Sachs L, Shaul Y. Regulation of p53 stability and p53-dependent apoptosis by NADH quinone oxidoreductase 1. Proc Natl Acad Sci U S A 2001; 98: 1188–93
   PubMed Web of Science ®Google Scholar
• Asher G, Lotem J, Kama R, Sachs L, Shaul Y. NQO1 stabilizes p53 through a distinct pathway. Proc Natl Acad Sci U S A 2002; 99: 3099–104
   PubMed Web of Science ®Google Scholar
• Ryk C, Kumar R, Sanyal S, Verdier PJ, Hemminki K, Larsson P, et al. Influence of polymorphism in DNA repair and defence genes on p53 mutations in bladder tumours. Cancer Lett 2005; Epub ahead of print.
   PubMed Web of Science ®Google Scholar
• Berggren P, Steineck G, Adolfsson J, Hansson J, Jansson O, Larsson P, et al. p53 mutations in urinary bladder cancer. Br J Cancer 2001; 84: 1505–11
   PubMed Web of Science ®Google Scholar
• Hu X, Herzog C, Zimniak P, Singh SV. Differential protection against benzoa.pyrene-7,8-dihydrodiol-9,10-epoxide-induced DNA damage in HepG2 cells stably transfected with allelic variants of pi class human glutathione S-transferase. Cancer Res 1999; 59: 2358–62
   PubMed Web of Science ®Google Scholar
• Ma Q, Lin G, Qin Y, Lu D, Golka K, Geller F, et al. GSTP1 A1578G (Ile105Val) polymorphism in benzidine-exposed workers: an association with cytological grading of exfoliated urothelial cells. Pharmacogenetics 2003; 13: 409–15
   PubMedGoogle Scholar
• Lin J, Spitz MR, Wang Y, Schabath MB, Gorlov IP, Hernandez LM, et al. Polymorphisms of folate metabolic genes and susceptibility to bladder cancer: a case-control study. Carcinogenesis 2004; 25: 1639–47
   PubMed Web of Science ®Google Scholar
• Le Marchand L, Wilkens LR, Kolonel LN, Henderson BE. The MTHFR C677T polymorphism and colorectal cancer: the multiethnic cohort study. Cancer Epidemiol Biomarkers Prev 2005; 14: 1198–203
   PubMed Web of Science ®Google Scholar
• Friso S, Girelli D, Trabetti E, Olivieri O, Guarini P, Pignatti PF, et al. The MTHFR 1298A > C polymorphism and genomic DNA methylation in human lymphocytes. Cancer Epidemiol Biomarkers Prev 2005; 14: 938–43
   PubMed Web of Science ®Google Scholar
• Kang S, Kim JW, Kang GH, Park NH, Song YS, Kang SB, et al. Polymorphism in folate- and methionine-metabolizing enzyme and aberrant CpG island hypermethylation in uterine cervical cancer. Gynecol Oncol 2005; 96: 173–80
   PubMed Web of Science ®Google Scholar
• Stankova J, Shang J, Rozen R. Antisense inhibition of methylenetetrahydrofolate reductase reduces cancer cell survival in vitro and tumor growth in vivo. Clin Cancer Res 2005; 11: 2047–52
   PubMed Web of Science ®Google Scholar